- Home
- Challenges in ATTR Amyloidosis: An Expert Debate
Challenges in ATTR Amyloidosis: An Expert Debate
- Amyloidosis
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
Radcliffe Medical Education bring together a globally-renowed faculty, including Prof Thibaud Damy (Creteil, FR) as he chairs a panel of distinguished experts, Dr Esther González López (Madrid, SP), Dr João R. Agostinho (Lisbon, PT) and Dr Ahmad Masri (Portland, USA) in a interactive symposium centred around three distinctive challenges facing physicians when diagnosing and treating ATTR-CM patients.
During this session, the panel discuss key challenges in ATTR Amyloidosis including identifying ATTR in regular cardiac clinic, managing patients with a mixed phenotype and disease modifying treating for ATTR-CM.
Disclosure
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘Individualising Antithrombotic Strategies for Established Coronary Artery Disease’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionalsand the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Support Statement
This Satellite Symposium was supported by an unrestricted educational grant from AstraZeneca who has no involvement in the content.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 90 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
- Heart Failure Specialists
- Cardiac Amyloidosis Specialists
- Echocardiologists
Learning Objectives
- Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
- Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
- Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
- Recall the limitations of existing therapies for ATTR-CM
- List the advantages of emerging classes of agents being evaluated in ATTR-CM
Module |
Title |
Duration |
Speakers |
---|---|---|---|
Session 1 | Welcome and Introduction | 2m 32s | Thibaud Damy |
Session 2 | Identifying ATTR in a Regular Cardiac Clinic | 19m 8s | Esther González López |
Session 3 | Managing Patients with a Mixed Phenotype | 16m 41s | João R Agostinho |
Session 4 | Disease Modifying Treatment for ATTR-CM | 16m 49s | Ahmad Masri |
Session 5 | Closing Remarks | 39s | Thibaud Damy |
Course Director
Speaker
Challenges in ATTR Amyloidosis: An Expert Debate's programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.